Skip to main content

Table 2 Vaccination parameters

From: The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study

Age class Vaccine efficacya Reference Vaccination coverage Reference (initial value)
Scenario 1 Scenario 2  
  TIV LAIV   TIV TIV LAIV  
1 year 11.0% N/A Vesikari et al. [41] 19.2% 19.2% --- Blank et al. [30]
2 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 19.2% 19.2% 22.4-50%b Blank et al. [30]
3-6 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 22.4% N/A 22.4-50%b Blank et al. [30]
7-10 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 23.6% N/A 23.6-50%b Blank et al. [30]
11-17 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 11.0% N/A 11.0-50%b Blank et al. [30]
18-59 years, normal risk 68.0% N/A Monto et al. [29] 14.5% 14.5% N/A Blank et al. [30]
18-59 years, elevated risk 58.0% N/A Jefferson et al. [28] 29.8% 29.8% N/A Blank et al. [31]
60-64 years 58.0% N/A Jefferson et al. [28] 33.1% 33.1% N/A Blank et al. [31]
65-69 years 58.0% N/A Jefferson et al. [28] 47.6% 47.6% N/A Blank et al. [31]
70 years and over 58.0% N/A Jefferson et al. [28] 53.4% 53.4% N/A Blank et al. [31]
  1. TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine; N/A not applicable.
  2. aVaccine efficacy determines the fraction of (previously susceptible) vaccinees who are immune due to vaccination at the peak of the following transmission season (i.e. 100 days after vaccination).
  3. bLAIV coverage increases in three annual steps from the initial to the final percentage.